Agenda and weblinks now available for the Neuromuscular Stakeholders meeting with FDA and NIH on AON therapies

We are pleased to announce that the agenda and live web streaming links are available for the FDA and NIH co-sponsored meeting ‘Antisense Oligonucleotide Therapies in Neuromuscular Diseases’, taking place on Monday 27th and Tuesday 28th September, 2010 in Washington DC, USA. We hope that stakeholders unable to attend the meeting in person, due to the limited number of spaces available, will be able to utilize these resources to follow the presentations and discussions.

The collaborative meeting will engage approximately 120 stakeholders from multiple different Neuromuscular Muscular Diseases concerned with AON development (Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, Myotonic Dystrophy and Spinal Muscular Atrophy) and is sponsored by Children’s National Medical Centre, CureDuchenne, Foundation to Eradicated Duchenne, MDA, Parent Project Muscular Dystrophy and TREAT-NMD.

The meeting will be structured into four sessions:

1: Toxicology & Preclinical Findings to Date
2: Biomarkers
3: Clinical Trial Design / Endpoints
4: Patient Registries and Assessing
Long-Term Outcomes

The goal of this meeting is to allow stakeholders to explore potential pathways forward for the AONs with the eventual goal of creating a sound scientific foundation for neuromuscular disease clinical development programs. These initial discussions should be seen as first steps to help pave the way for future discussions and collaborations.

Download the AON Meeting Agenda.

Connect to the live web stream.